Literature DB >> 26635034

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.

Gaëlle Fossard1, Emilie Blond2, Marie Balsat1, Stéphane Morisset1, Stéphane Giraudier3, Martine Escoffre-Barbe4, Hélène Labussière-Wallet1, Maël Heiblig1, Arthur Bert1, Madeleine Etienne5, Jocelyne Drai2, Mohamad Sobh1, Isabelle Redonnet-Vernhet6, Jean-Christophe Lega7, François-Xavier Mahon8, Gabriel Etienne8, Franck Emmanuel Nicolini9.   

Abstract

Entities:  

Keywords:  BCR-ABL; cardiovascular events; chronic phase CML; homocysteine; nilotinib

Mesh：

Substances：

Year:  2015        PMID： 26635034      PMCID： PMC4815734          DOI： 10.3324/haematol.2015.135103

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Plasma homocysteine levels and mortality in patients with coronary artery disease.

Authors:  O Nygård; J E Nordrehaug; H Refsum; P M Ueland; M Farstad; S E Vollset
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

2.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Authors:  Susan M Graham; Heather G Jørgensen; Elaine Allan; Charlie Pearson; Michael J Alcorn; Linda Richmond; Tessa L Holyoake
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

3.  Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

Authors:  Peter Valent; Emir Hadzijusufovic; Gerit-Holger Schernthaner; Dominik Wolf; Delphine Rea; Philipp le Coutre
Journal:  Blood       Date:  2014-12-18       Impact factor: 22.113

4.  The human cystathionine beta-synthase (CBS) gene: complete sequence, alternative splicing, and polymorphisms.

Authors:  J P Kraus; J Oliveriusová; J Sokolová; E Kraus; C Vlcek; R de Franchis; K N Maclean; L Bao; D Patterson; V Paces; W Ansorge; V Kozich
Journal:  Genomics       Date:  1998-09-15       Impact factor: 5.736

5.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Authors:  Hagop Kantarjian; Francis Giles; Lydia Wunderle; Kapil Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

7.  Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Authors:  Zdenek Racil; Filip Razga; Jana Drapalova; Lucie Buresova; Daniela Zackova; Martina Palackova; Lukas Semerad; Ludmila Malaskova; Martin Haluzik; Jiri Mayer
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

8.  Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

Authors:  T D Kim; D Rea; M Schwarz; P Grille; F E Nicolini; G Rosti; L Levato; F J Giles; H Dombret; T Mirault; H Labussière; R Lindhorst; W Haverkamp; I Buschmann; B Dörken; P D le Coutre
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528

9.  Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Authors:  F J Giles; P D le Coutre; J Pinilla-Ibarz; R A Larson; N Gattermann; O G Ottmann; A Hochhaus; J P Radich; G Saglio; T P Hughes; G Martinelli; D-W Kim; S Novick; K Gillis; X Fan; J Cortes; M Baccarani; H M Kantarjian
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  3 in total

1.  High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Zhiheng Cheng; Yifeng Dai; Yifan Pang; Yang Jiao; Yan Liu; Longzhen Cui; Tingting Qian; Liang Quan; Wei Cui; Yue Pan; Xu Ye; Jinlong Shi; Lin Fu
Journal:  Cancer Biol Ther       Date:  2019-07-15       Impact factor: 4.742

2.  Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Authors:  Preetesh Jain; Hagop Kantarjian; Prajwal C Boddu; Graciela M Nogueras-González; Srdan Verstovsek; Guillermo Garcia-Manero; Gautam Borthakur; Koji Sasaki; Tapan M Kadia; Princy Sam; Hycienth Ahaneku; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Jorge E Cortes
Journal:  Blood Adv       Date:  2019-03-26

3.  The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.

Authors:  Hélène Haguet; Céline Bouvy; Anne-Sophie Delvigne; Elise Modaffari; Adeline Wannez; Pierre Sonveaux; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.